- Clinical Trials
- December 2019
- 908 Pages
Global
From €2417EUR$2,500USD£2,076GBP
- Report
- October 2019
- 117 Pages
Europe
€4592EUR$4,750USD£3,945GBP
- Report
- May 2022
- 90 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- June 2019
- 130 Pages
United States
€2896EUR$2,995USD£2,487GBP
- Report
- March 2020
- 289 Pages
Global
From €5192EUR$5,370USD£4,459GBP
- Report
- March 2023
- 147 Pages
Global
From €5800EUR$5,999USD£4,982GBP
- Book
- October 2020
- 288 Pages
- Book
- October 2019
- 632 Pages
- Book
- April 2018
- 776 Pages
United States
- Book
- January 2016
- 368 Pages
- Book
- May 2013
- 400 Pages
- Book
- October 2018
- 308 Pages
- Book
- May 2021
North America
Bladder cancer is a type of cancer that affects the urinary bladder. It is the sixth most common type of cancer in the United States and the fourth most common type of cancer in Europe. Symptoms of bladder cancer include blood in the urine, pain during urination, and frequent urination. Treatment options for bladder cancer include surgery, chemotherapy, radiation therapy, and immunotherapy.
The oncology market for bladder cancer is highly competitive, with a range of treatments available. Pharmaceutical companies are developing new treatments to improve outcomes for patients, such as targeted therapies and immunotherapies. Additionally, research is being conducted to better understand the biology of bladder cancer and to develop new diagnostic tests.
Companies in the bladder cancer market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more
